Sanofi India Ltd
Company Profile
Business description
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and other export markets.
Contact
Saki Vihar Road
Sanofi House, CTS Number 117-B
L&T Business Park
Powai
MumbaiMH400072
INDT: +91 2228032000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
1,285
Stocks News & Analysis
stocks
Undervalued ASX share showing progress in global efforts
stocks
Bookworm: Is this the secret to exceptional long-term returns?
stocks
Unconventional wisdom: Are dividends the answers?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,955.90 | 21.60 | 0.24% |
CAC 40 | 7,834.58 | 16.30 | 0.21% |
DAX 40 | 24,217.50 | 78.43 | -0.32% |
Dow JONES (US) | 44,901.92 | 208.01 | 0.47% |
FTSE 100 | 9,120.31 | 18.06 | -0.20% |
HKSE | 25,579.40 | 191.05 | 0.75% |
NASDAQ | 21,108.32 | 50.36 | 0.24% |
Nikkei 225 | 41,148.07 | 308.16 | -0.74% |
NZX 50 Index | 12,909.69 | 56.23 | 0.44% |
S&P 500 | 6,388.64 | 25.29 | 0.40% |
S&P/ASX 200 | 8,690.50 | 23.60 | 0.27% |
SSE Composite Index | 3,601.80 | 8.15 | 0.23% |